New Study Shows Good Effects Of Calcitonin

16 September 1997

Osteoporotic women with a history of vertebral fractures may be able toreduce the risk of additional vertebral fractures by taking salmon calcitonin nasally, according to a study presented at the ASBMR meeting.

The PROOF (Prevent Recurrence of Osteoporotic Fractures) study involved over 1,000 postmenopausal women with osteoporosis. The study found that patients receiving salmon calcitonin nasally were 37% less likely to develop new vertebral fractures than the control group. Following three years of treatment, Reuters reports, 12% of the women receiving active therapy had developed new vertebral fractures, against 20% of the placebo group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight